Grifols Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Grifols ha un patrimonio netto totale di €8.0B e un debito totale di €9.9B, che porta il suo rapporto debito/patrimonio netto a 123.2%. Le sue attività totali e le sue passività totali sono rispettivamente €20.3B e €12.3B. L'EBIT di Grifols è €971.7M rendendo il suo rapporto di copertura degli interessi 1.8. Ha liquidità e investimenti a breve termine pari a €806.7M.

Informazioni chiave

123.2%

Rapporto debito/patrimonio netto

€9.85b

Debito

Indice di copertura degli interessi	1.8x
Contanti	€806.74m
Patrimonio netto	€8.00b
Totale passività	€12.29b
Totale attività	€20.28b

Aggiornamenti recenti sulla salute finanziaria

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Feb 20

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Nov 10

Recent updates

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

May 21

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Apr 20

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Mar 01

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 20

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €5.3B ) di GRF superano le sue passività a breve termine ( €2.4B ).

Passività a lungo termine: Le attività a breve termine di GRF ( €5.3B ) non coprono le sue passività a lungo termine ( €9.9B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 113.1% ) di GRF è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di GRF si è ridotto da 138.3% a 123.2% negli ultimi 5 anni.

Copertura del debito: Il debito di GRF non è ben coperto dal flusso di cassa operativo ( 5.3% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di GRF non sono ben coperti dall'EBIT ( 1.8 x copertura).

Grifols Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Recent updates

Brookfield Capital Partners (Uk) Limited and Grifols family cancelled the acquisition of remaining stake in Grifols, S.A. (BME:GRF).

Consensus EPS estimates fall by 24%

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Third quarter 2024 earnings released

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Investor sentiment improves as stock rises 15%

Second quarter 2024 earnings: EPS misses analyst expectations

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Investor sentiment deteriorates as stock falls 16%

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

New minor risk - Earnings quality

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

First quarter 2024 earnings released

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Price target decreased by 7.1% to €17.40

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 23%

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: Revenues in line with analyst expectations

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 12%

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

New major risk - Share price stability

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings released

Consensus EPS estimates increase by 45%

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Consensus EPS estimates increase by 46%

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane